LNCRNA LYPLA 1-2 INHIBITS GLIOMA DEVELOPMENT BY REGULATING THE MIR-217-5P/CCR7 AXIS

Guanliang Wang¹, Zihui Xu², Kailong Lin¹, Sen Mu³, Yicheng Pan¹, Mengya Shan², Liusheng Chen^{3, *} 

¹Department of Traditional Chinese Medicine Rehabilitation and Physiotherapy, Army 75th Group Military Hospital, Dali 671003, PR China - ²Department of Traditional Chinese Medicine, Second Affiliated Hospital of Army Medical University, Chognqing 400037, PR China - ³Medical Research Center, Army 75th Group Military Hospital, Dali 671003, PR China

Objective: To investigate the mechanism of long-chain non-coding RNA lypla 1-2 (lncrna lypla 1-2) inhibiting the development of glioma. 

Method: Glioma and peritumoral tissues of 45 patients with glioma were randomly selected. To observe the expression of lyplal 1-2 in gliomas and peritumoral tissues, the human glioma cell line (U251) was selected, and U251 cells were infected with lentivirus. Lyplal 1-2 overexpression and blank control groups were constructed to observe the invasion and migration ability of two groups of cells in U251 cells. Eight SPF-grade BALB/c mice were randomly selected and injected into the tail vein of glioma mice to observe the change of glioma size in both lyplal 1-2 overexpression and control groups. The expression levels of mir-217-5p and CCR7 in lyplal 1-2 overexpression and control groups were determined by western blotting. 

Result: Compared with peritumoral tissue, lyplal 1-2 expression in gliomas decreased significantly (P < 0.05). Compared with the control group, the invasion and migration abilities of the LYPLAL 1-2 overexpression group were significantly reduced, and the glioma volume of the LYPLAL 1-2 overexpression group was significantly reduced (P<0.05). Compared with the control group, lypla 1-2 expression in the overexpression group was significantly higher, and the expression levels of mir-217-5p and CCR7 were significantly lower (P<0.05). 

Conclusion: Lyplal 1-2 can decrease the growth, invasion, and metastasis of glioma by inhibiting the expression of the mir-217-5p/CCR7 axis. This axis may, therefore, represent a highly suitable target for glioma treatment.